1. Catalog
  2. GREQH2EM2403 - CME/CMLE - Updates in HER2-directed ...
Image For Activity Cover
GREQH2EM2403 - CME/CMLE - Updates in HER2-directed Therapies in Solid Tumors
Course Description

Updates in HER2-directed Therapies in Solid Tumors  

Activity Description: 

This microlearning activity is designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of emerging research in pan-tumor HER2 testing and of  treatment options based on HER2 results.  A particular focus of this activity is the DESTINY-Pan Tumor02 study and the latest evidence regarding HER2 testing, scoring and reporting. The microlearning design of this activity allows for a brief and focused exploration of this topic. 

Course topics include: 

  • HER2-directed therapies 

  • DESTINY-PanTumor02 study and FDA approvals 

  • HER2 testing, scoring and reporting 

  • Treatment implications based on HER2 results   

Faculty/Authors 

Marilyn M. Bui, MD, PhD, FCAP  

Senior Member & Professor, Departments of Pathology & Machine Learning, Scientific Director of Analytic Microscopy Core, Moffitt Cancer Center & Research Institute  

Tampa, Florida, US 


Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement 

CME/CMLE Credit: 0.25
Estimated Completion Time: 0.25 hour
Format: Online educational activity 


Target Audience  

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.

 
Credit Designation Statement  

The ASCP designates this activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.  

ASCP designates this activity for a maximum of .25 CMLE credit.  This activity meets CMP and state re-licensure requirements for laboratory personnel.  

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT. 

Method of Participation  

To complete the activity and receive credit, the participant must participate in the course. CME certificates will be provided on-line.  

Commercial Support 

This activity is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc. 

Instructions

To claim CME/CMLE credit for the exercise, do the following:

  1. Review the Faculty Disclosure.
  2. Click Go to Content and click the first module of the course.
  3. Complete the Demographic Survey.
  4. Complete the Pre-Test.
  5. Review the Educational Activity.
  6. Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
  7. Submit the course Evaluation.
  8. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.
Faculty Disclosure

Release Dates: 10/21/2024  
Review Date:
Expiration Date: 10/21/2027  

 

Course Objectives

Upon completion of this activity, you will be able to:

  • Describe the evolving science behind HER2-directed therapies 
  • Summarize the recent DESTINY-PanTumor02 study and FDA approvals
  • Identify methods of HER2 testing, scoring, and reporting
  • Discuss treatment implications for patients based on HER2 results 
Summary
Availability: On-Demand
Credit Offered:
0.25 CME/CMLE Credit
Powered By